Haematology

Haematology Referrals 

Email: haematologyreferrals@svha.org.au

Fax: 9231 2759

For Urgent Haematology Referrals:

Contact SVHM Switchboard directly: 03 9231 2211

Request to be connected to either Professor Hang Quach or Associate Professor Matthew Ku's mobile.

For Haematology Clinical Trial referral queries:

Email: Anupa Dey on anupa.dey@svha.org.au

 

Our Team

Professor HANG QUACH – MBBS, SpecCertOC, FRACP, FRCPA, MD
Director of Clinical Haematology + Clinical Haematology Research
Hang

Professor Hang Quach is the head of the Department of Clinical Haematology and is the director of Clinical Haematology Research at St Vincent’s Hospital Melbourne. She is a professor of haematology at the University of Melbourne. Her clinical and translational research focuses on novel therapeutics and their impact on the immunology and the microenvironment in multiple myeloma. As of December 2021, she has secured competitive research funding of more than 13 million AUD towards myeloma research and is highly published in the field of in multiple myeloma. Prof. Quach is also the deputy-chair of the Myeloma Scientific Advisory Group (MSAG) for Myeloma Australia, where she leads the development and biennial update of the Australian National Treatment Guideline for Multiple Myeloma. She is also the co-chair of the Myeloma Working Group of the Australasian Lymphoma Leukaemia Group (ALLG). She is passionate about improving the standard of care for patients with blood cancers in Australia, not only through clinical care, but also through research and active roles on steering committees of national and international health care groups.
Associate Professor MERROLE COLE-SINCLAIR – MBBS FRACP FRCPA
Director of laboratory Haematology
Merrole

Associate Professor Merrole Cole-Sinclair is a clinical and laboratory haematologist with more than 30 years’ specialist experience. She holds honorary academic positions with the Department of Pathology at the University of Melbourne and the Department of Epidemiology and Preventive Medicine at Monash University. She has received Honorary Life Memberships of the Haematology Society of Australia and New Zealand and the Australian and New Zealand Society of Blood Transfusion and various University and College teaching awards. She is a member of the Council of the Victorian Institute of Forensic Medicine, the National Pathology Accreditation Advisory Council and the Victorian Serious Transfusion Incident Reporting advisory group. She has been a recent Board member of the Royal College of Pathologists of Australasia (RCPA) and Chair of the Australian Committee for Joint College Training in Haematology (Royal Australasian College of Australasia/RCPA). Her clinical interests are in general diagnostic and clinical haematology and transfusion.
Associate Professor MATTHEW KU – MBBS, FRACP, FRCPA, PhD
Matthew

A/Prof Ku is a haematologist with an interest in lymphoproliferative neoplasms. He is currently the Deputy Director of the Haematology Clinical Research Unit, and the Clinical Stream Lead for Aggressive Lymphomas. He is the Lead for the Immune Effector Cell Therapy Steering Committee, with a special interest in immunotherapies. He is the Principal Investigator on multiple international clinical trials that utilise novel therapies in lymphomas, with the aim of improving patient outcomes. A/Prof Ku is the current chairperson for the Membership Relations Working Group of the Australasian Leukaemia and Lymphoma Group, and he is a member of the Australasian Lymphoma Alliance, the Australasian Leukaemia & Lymphoma Group, the Haematology Society of Australia and New Zealand, and the American Society of Hematology. A/Prof Ku is also the current Chair for the St Vincent’s Grand Round Committee, and the Haematology Lead for Cancer Centre Outpatient Clinics. A/Prof Ku's PhD focused on novel pathways in acute myeloid leukaemia, and subsequently his postdoctoral Lymphoma Clinical Fellowship involved managing complex patients on clinical studies. A/Prof Ku has multiple publications in peer-reviewed international journals. He has also presented at many national and international haematology conferences and meetings. Outside of work, A/Prof Ku’s main interests are biking riding with his family, watching sci-fi movies, and sharing a nice meal with his wife.
Dr ROBIN FILSHIE – MBCHB, FRACP, FRCPA, PhD
Robin

Dr Robin Filshie has been a consultant clinical and laboratory Haematologist at St.Vincent’s Hospital Melbourne since 1999. He has a broad expertise across the fields of benign and malignant haematology and is actively involved in clinical trials in a wide range of haematological malignancies at St Vincent’s Public Hospital. He is longstanding member of The Australasian Leukaemia and Lymphoma Group (ALLG) and current member of the ALLG Safety and Data Monitoring Committee. He is also a past chair of the St Vincent’s Hospital Human Research Ethics Committee. He is a keen cyclist and hopes to be able to combine that with some future travel.
Dr MASA LASICA – MBBS, FRACP, FRCPA,
Masa

Dr Masa Lasica is haematologist and clinical researcher at St Vincent’s Hospital, Melbourne where she leads the indolent lymphoma, Chronic Lymphocytic Leukaemia (CLL) and amyloidosis program. Masa graduated from the Australian National University School of Medicine in 2008 and completed her haematology specialist training in Melbourne. In 2017 she was awarded fellowship of the Royal Australasian College of Pathologists and the Royal Australian College of Physicians. She undertook a fellowship at the Transfusion Research Unit, Monash University and Australian Red Cross Blood Service as well as a Trials Fellowship at Eastern Health. Masa’s clinical research focuses on the use of novel agents to improve outcomes in patients with indolent lymphoma, CLL and multiple myeloma. In 2022, she was awarded the RACP Research Entry Scholarship. She is principal and sub-investigator on a number of clinical studies and is a member of the Australasian Leukaemia and Lymphoma Group.
Dr SHUH YING TAN – MBBS, FRACP, FRCPA.
Shuh 

Dr Tan is a consultant haematologist, and the clinical lead for acute myeloid leukaemia, myelodysplastic syndromes, and myeloproliferative disorders. She has a special interest in myeloid disorders, with a focus on the development of novel therapies to improve patient outcomes. She is committed in bridging the inequitable access to treatment, and led the establishment of clinical trials in regional centres and interstate. She also champions the training and mentoring of junior doctors. She is a member of scientific committees in the Australasian Leukaemia and Lymphoma Group, and is also an active member of several other committees including thrombosis, transfusion, and cancer governance.
Associate Professor ALI BAZARGAN – MD, FRACP.
Ali

Associate Professor Ali Bazargan is a senior clinical haematologist at St. Vincent's Hospital. He has a special interest in lymphomas, Langerhans cell histiocytosis and thrombosis. He is the lead clinician for Hodgkin lymphoma and T cell lymphomas and was the former chair of thrombosis committee at St. Vincent's Hospital. He is the principal and sub-investigator in a number of clinical trials. He is an active member of a number of committees and is an international working party member for perioperative management of anticoagulation in International Society of Thrombosis and Haemostasis. He remains a working party member of high-grade lymphoma committee in Australiasian Leukaemia and Lymphoma Group.
Dr SLAVISA NINKOVIC – MBBS, FRACP, FRCPA,
 Slavia  

Dr Ninkovic graduated from the University of Melbourne in 2008, completing advanced training in clinical and laboratory haematology through St. Vincent’s Hospital and the Peter MacCallum Cancer Centre. After an 18 month clinical fellowship at the University College Hospital in London, he returned to St. Vincent’s where he is currently practicing as a clinical and laboratory haematologist and a molecular haematopathologist at the Victorian Cancer Cytogenetics Service. Dr Ninkovic is currently enrolled in a PhD centred on a clinical study assessing a response-adapted approach to treatment of transplant ineligible multiple myeloma patients. Translational research focusing on the immune tumour microenvironment and genomic aberrations in myeloma are integral components of his research activity. He is most excited by advancing developments in the field of diagnostic Haematopathology and how they continually bring us a step closer to delivering personalised treatments for patients with haematological malignancies.
Dr SHIRLENE SIM – MBBS, FRACP, FRCPA,
Shirline

Dr Sim is a dual-trained clinical and laboratory haematologist. After graduating from The University of Melbourne, she went on to complete her basic physician and advanced haematology training at St Vincent’s Hospital, Peter MacCallum Cancer Centre and Royal Melbourne Hospital. She is currently involved in clinical trials and research at St Vincent’s Hospital, and is currently pursuing a higher degree. Dr Sim has a wide interest in both malignant and non-malignant haematology, and is highly dedicated to providing the best possible care to all her patients
Dr KRITIKA CHAIWATANATORN – MBBS, FRACP, FRCPA, PhD
Kritika

Dr Kritika Chaiwatanatorn is a consultant clinical and laboratory haematologist at St Vincent’s hospital. She completed her medical undergraduate degree and postgraduate degree in lymphoma research through the University of Melbourne. She is a fellow of both the Royal Australasian College of Physicians (RACP) as well as the Royal College of Pathologists of Australasia (RCPA). Her interest is in laboratory and general clinical haematology with a specific focus in thrombosis and haemostasis. She is the Chair of St Vincent’s Hospital Venous Thromboembolism (VTE) Steering Committee and actively contributes to St Vincent’s Hospital VTE and anticoagulation related policies. She is the Lead Haematologist of St Vincent’s Thrombosis Clinic and in the Coagulation Department of St Vincent’s Pathology. She has a passion for training the next generation of haematologists.
Dr ANNE DYKES – B.Sc. (Hons), MBChB. MRCP, FRACP, FRCPA
 Anne

Dr Anne Dykes trained in Medicine in Scotland before moving to Melbourne where she specialised in Haematology. She works as a senior Haematologist in the Laboratory and Clinic at St Vincent's Hospital. She is also the Coordinator for Haematology Training in Victoria, Tasmania and NT.

Dr JEREMY ONG – Clinical Haematologist

Jeremy ong

 

Dr Jeremy Ong is a dual-trained clinical and laboratory haematologist. Graduating from The University of Melbourne, he completed physicians training at St Vincent's Hospital, before undertaking haematology advanced training at The Alfred and Monash Health.

Dr Ong has a keen interest in non-malignant blood conditions, particularly thrombosis, bleeding disorders and perioperative care. He also treats blood cancers including lymphoma, myeloma and myeloid disorders, and is an active investigator on clinical trials at St Vincent's Public Hospital. He has presented at national and international conferences, as well as published in peer-reviewed journals, allowing him to provide optimal evidence-based care for his patients.

Dr MATTHEW REES – Clinical Haematologist

Rees, Matthew J._30252415_20230703 (2)

Dr Matthew Rees is a haematologist with an interest in myeloma, amyloidosis and lymphoma. He was the top-graduating student from the University of Melbourne, MD class of 2014. He completed his haematology training at Peter MacCallum Cancer Centre, the Austin and Royal Melbourne Hospitals, in addition to an advanced dysproteinemias fellowship at the Mayo Clinic.

His research is focused on immunotherapy in multiple myeloma and organ recovery in light chain (AL) amyloidosis. He has presented research on these topics at multiple international meetings, including an oral presentation at the American Society of Clinical Oncology. He is a member of the myeloma working group of the Australasian Leukaemia Lymphoma Group (ALLG) and disease lead for light chain (AL) amyloidosis at St Vincent's Hospital Melbourne.

Haematology Clinical Research Centre Trials Open to Recruitment

For more information on clinical trials please contact:

Lisa Demosthenous
Manager of Haematology Clinical Research Centre
lisa.demosthenous@svha.org.au

Alternative contact:

Anupa Dey
Deputy Manager of Haematology Clinical Research Centre
anupa.dey@svha.org.au

Prof Hang Quach, MBBS (Hons) SpecCertOC FRACP FRCPA MD
Director | Clinical Haematology Service | St Vincent’s Hospital

Director | Clinical Haematology Research | St Vincent’s Hospital
hang.quach@svha.org.au

A/Prof Matthew Ku, MBBS SpecCertOC FRACP FRCPA PhD
Deputy Director of Haematology Clinical Research Unit | St Vincent’s Hospital
Haematologist & Lymphoma Lead | St Vincent’s Hospital
mathew.ku@svha.org.au

Multiple Myeloma

ALLG MM23 SeaLAND (ND MM)

An ALLG phase 3 randomised trial of Selinexor and Lenalidomide versus lenalidomide maintenance post Autologous stem cell transplant for patients with Newly Diagnosed multiple myeloma

Newly Diagnosed

GSK2857916 DREAMM 9 (209664) (ND MM)

A Phase 3, Randomized, Open-Label Study of Belantamab Mafodotin Administered in Combination with Bortezomib, Lenalidomide and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone Alone in Participants with Newly Diagnosed Multiple Myeloma who are Ineligible for Autologous Stem Cell Transplantation

Pfizer MAGNETISMM-6 (ND MM)

AN OPEN-LABEL, 2-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) + DARATUMUMAB + LENALIDOMIDE VERSUS

Pfizer MAGNETISMM-7 (ND MM)

A RANDOMIZED, 2-ARM, PHASE 3 STUDY OF ELRANATAMAB (PF-06863135) VERSUS LENALIDOMIDE IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA AFTER UNDERGOING AUTOLOGOUS STEM-CELL TRANSPLANTATION

ALLG MM26 NORM

Novel Combinations for Orphan Myeloma: The NORM Platform Study

Abbvie M21-406 (R/R MM)

First In Human Study of the BCL-2 Inhibitor ABBV-453 in Biomarker Selected Subjects with Relapsed or Refractory Multiple Myeloma.

Abbvie M22-947 (R/R MM)

A Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

ALLG MM25 Viber-M (R/R MM)

A phase Ib/II study of Venetoclax, Iberdomide and Dexamethasone for patients in first or second relapse of Multiple Myeloma with t(11;14)

AMaRC 20-01 IBIS ( R/R MM)

An immuno-therapeutic salvage strategy for ‘functional’ high-risk (FHR) multiple myeloma incorporating Iberdomide, Isatuximab and Dexamethasone (IBIS)

Relapsed/

Refractory

AMaRC 19-02 BelaCarD (R/R MM)

A phase I/II single arm study of combination Belantamab Mafodotin, Carfilzomib, Dexamethasone in patients with early relapsed multiple myeloma.

BGB-11417-105 (R/R MM)

A Phase 1b/2 Dose-Escalation and Cohort-Expansion Study to Determine the Safety and Efficacy of BGB-11417 in Combination With Dexamethasone and Carfilzomib/Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma and t(11;14)

BMS CA057-001 Successor -1 (R/R MM)

A phase 3, two- stage randomised multicentre open label study comparing CC-92480, Bortezomib and dexamethasone (480Vd) Vs Pomalidomide, Bortezomib and dexamethasone (PVd) in subjects with relapsed or refractory multiple myeloma (RRMM)

BMS CA057-008 Successor -2 (R/R MM)

A Phase 3, Two-stage, Randomized, Multicenter, Open-label Study Comparing CC-92480

(BMS-986348), Carfilzomib, and Dexamethasone (480Kd) Versus Carfilzomib and Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma (RRMM)

CC-220-MM-002 EXCALIBER (R/R MM)

A Phase 3, Randomized, Multicenter, Open-Label Study Comparing Iberdomide, Daratumumab And Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, And Dexamethasone (Dvd) In Subjects With Relapsed Or Refractory Multiple Myeloma

Genetech GO43227 (CAMMA 3) R/R MM)

A Phase 1b, Open Label, Multicentre, Trial evaluating the safety, pharmacokinetics, and activity of subcutaneous cevostaman (BFCR4350A) in patients with replapsed or refractory multiple myelomas (CAMMA3)

GSK 208887 DREAMM 5 (R/R MM)

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) in Combination with Anti- Cancer Treatments in Participants with Relapsed/Refractory Multiple Myeloma

GSK 218670 DREAMM20 (R/R MM)

A Phase 1/2 open-label, multicentre, dose escalation and expansion study to investigate the safety, tolerability, and clinical activity of belantamab as monotherapy and in combination with other treatments in participants with multiple myeloma.

IBS 2001-101 (R/R MM)

A Phase 1, First-in-Human, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma

Janssen MajesTEC-9 (R/R MM)

A Phase 3 Randomized Study Comparing Teclistamab Monotherapy versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants with Relapsed or Refractory Multiple Myeloma who have Received 1 to 3 Prior Lines of Therapy, Including an Anti-CD38 Monoclonal Antibody and Lenalidomide

Janssen MonumenTAL-2 (R/R MM)

A Multi-arm Phase 1b Study of Talquetamab with Other Anticancer Therapies in Participants with Multiple Myeloma

Janssen RedirecT-1 (R/R MM)

A Phase 1b/2 Dose Escalation and Expansion Study of the Combination of the Bispecific T Cell Redirection Antibodies Talquetamab and Teclistamab in Participants with Relapsed or Refractory Multiple Myeloma

Novotech ICHNOS ISB 1442-101 (R/R MM)

A Phase 1/2, First-in-Human, Multicenter, Open-Label, Dose Escalation and Dose-Expansion Study of Single-Agent ISB 1442 in Patients with Relapsed/Refractory Multiple Myeloma

Novotech ISB 2001-101 (R/R MM)

A Phase 1, First-in-Human, Multicenter, Open-Label, Dose-Escalation and Dose-Expansion Study of Single-Agent ISB 2001 in Subjects with Relapsed/Refractory Multiple Myeloma.

Pfizer MAGNETISMM-5 (R/R MM)

An open-label, 3-arm, Multicenter, Randomized Phase 3 Study to Evaluate the efficacy and safety of Elranatamab (pf-06863135) Monotherapy and Elranatamab + Daratumumab versus Daratumumab + Pomalidomide + Dexamethasone in participants with Relapsed/Refractory Multiple Myeloma who have received at least 1 prior line of therapy including Lenalidomide and a proteasome inhibitor.

Regeneron (R/R MM)

AN OPEN-LABEL, RANDOMIZED, PHASE 3 STUDY OF LINVOSELTAMAB (REGN5458; ANTI-BCMA X ANTI-CD3 BISPECIFIC ANTIBODY) VERSUS THE COMBINATION OF ELOTUZUMAB, POMALIDOMIDE, AND DEXAMETHASONE (EPd), IN PATIENTS WITH

RELAPSED/REFRACTORY MULTIPLE MYELOMA (LINKER-MM3)

Roche CO43476 (CAMMA-2)

A phase 1/11, open-label, multi-cohort study to evaluate the efficacy and safety of cevostamab in prior b cell maturation antigen-exposed patients with relapsed/refractory multiple myeloma

Roche CO43923 Platform Study (Plycom)

A PLATFORM STUDY EVALUATING THE SAFETY AND EFFICACY OF MULTIPLE TREATMENTS IN PATIENTS WITH MULTIPLE MYELOMA

SANOFI ACT16482 UMBRELLA (R/R MM)

Phase 1-2 UMBRELLA trial evaluating isatuximab with or without dexamethasone in combination with novel agents compared to isatuximab with pomalidomide and dexamethasone in relapsed or refractory multiple myeloma (RRMM)

Sanofi EFC15951 Iraklia (R/RMM)

A randomized, Phase 3, open label study evaluating subcutaneous versus intravenous administration of isatuximab in combination with pomalidomide and dexamethasone in adult patients with relapsed and/or refractory multiple myeloma (RRMM)

Sanofi ACT17453 Izalco (R/RMM)

A randomized, Phase 2, open label study evaluating subcutaneous administration of isatuximab in combination with carfilzomib and dexamethasone in adult participants with relapsed and/or refractory multiple myeloma (RRMM)

Acute Myeloid Leukaemia & Myelodysplastic Syndrome

Newly diagnosed

ALLG AML M23 (HOVON) (TN AML, TN MDS)

A phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib or enasidenib in combination with induction therapy and consolidation therapy followed by maintenance therapy in patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndrome with excess blasts-2, with an IDH1 or IDH2 mutation, respectively, eligible for intensive chemotherapy.

ALLG AML M25 (INTERVENE) (ND AML)

An ALLG Phase 2 study to Investigate Novel Triplets to Extend Remission with VENetoclax in Elderly (INTERVENE) Acute Myeloid Leukaemia

KER050-MD-201 (ND MDS)

A Phase 2, Open-Label, Ascending Dose Study of KER-050 for the Treatment of Anemia in Patients with Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS)

Relapsed Refractory

APTOSE HM-FLT-101 (R/R AML)

A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM43239 in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML)

BGB-11417-103 (R/R Myeloid Malignancies)

A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid Malignancies

BMS CA059-001 (R/R AML MDS)

A phase 1, open-label, dose finding study of CC-95251 alone and in combination with Antineoplastic agents in subjects with Acute Myeloid Leukemia and Myelodysplastic syndromes

Myelofibrosis

Relapsed Refractory

Pharmaxis (R/R MF)

A phase 1/2a study to evaluate safety, pharmacokinetic and pharmacodynamic dose escalation and expansion study of PXS-5505 in patients with primary, post-polycythemia vera or post-essential thrombocythemia myelofibrosis

Relapsed Refractory

KER050-MF-301 (R/R MF)

A Phase 2 Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of KER-050 as Monotherapy or in Combination with Ruxolitinib in Participants with Myelofibrosis

Chronic Lymphocytic Leukaemia

Treatment Naïve & Relapsed Refractory

BGB-11417-101 (TN, R/R CLL)

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

Relapsed Refractory

LOXO-BTK-20022 (R/R CLL)

Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-322)

PCYC-1145-LT (R/R CLL)

Extended treatment protocol for subjects continuing to benefit from ibrutinib after completion of ibrutinib clinical trials

BGB-16673-101 (RR CLL)

A Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

AbbVIE- M22-716 (B Cell)

A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Waldenström Macroglobulinemia

Treatment Naïve &

Relapsed Refractory

BGB-11417-101 (B Cell)

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

BGB- 16673-101 (RR B-Cell Malignancies)

Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

Lymphomas

AbbVIE- M22-716 (B Cell)

A First-In-Human Multicenter, Open-Label Study to Determine the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ABBV-319 in B-cell Malignancies

Treatment Naïve &

Relapsed Refractory

ALLG NHL30 PETReA (TN FL)

Phase 3 evaluation of PET-guided, Response-Adapted therapy in patients with previously untreated, high tumour burden follicular lymphoma

BGB-11417-101 (R/R) B-cell NHL

A Phase 1/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients with Mature B-Cell Malignancies

BGB- 16673-101 (RR B-Cell Malignancies)

Phase 1, Open-Label, Dose-Escalation and -Expansion Study of the Bruton Tyrosine Kinase-Targeted Protein-Degrader BGB-16673 in Patients With B-Cell Malignancies

BGB-3111-308 (RR MZL/FL)

A Phase 3 Randomized, Open-Label, Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

GENMAB GCT3013-01 (R/R DLBCL and FL)

A Phase 1/2, Open-Label, Dose-Escalation Trial of GEN3013 in Patients with Relapsed, Progressive or Refractory B-Cell Lymphoma

MERCK (MK-4280-003) (R/R HL, DLBCL, NHL)

A Phase 1/Phase 2 Clinical Study to Evaluate the Safety and Efficacy of a Combination of MK-4280 and Pembrolizumab (MK-3475) in Participants with Hematologic Malignancies

Bleeding Disorders

DIAAMOND (Aplastic Anaemia)

Section A: Avatrombopag plus up Front ImmunosuppReSsive Therapy in treatment-naive severe aplastic anaemia - The DIAAMOND Ava-FIRST Trial

Section B: Avatrombopag iN Relapsed or Refractory severe aplastic anaemia as EXtra Therapy – The DIAAMOND Ava-NEXT Trial

Registries / Other

Myeloma 1000 Registry

The Myeloma 1000 Project

MRDR Registry

Myeloma & Related Diseases Registry

NBCR

Australasian Leukaemia and Lymphoma Group National Blood Cancer Registry (previously known as AMLM18)

LaRDR (Lymphoma and Related Disease Registry)

Lymphoma and Related Diseases Registry (LaRDR)
  

Health Pathways

HealthPathways Melbourne is an online portal designed to be used by general practice at the point of care to guide best practice assessment, management and referral of common clinical conditions.

 

Please Note:
This is a public outpatient service. All patients need to be referred to us by a GP. Please see your GP if you believe you would benefit from a referral to this clinic. Many doctors have private consulting suites as well as working in the public hospital system. This is entirely separate from St Vincent’s and our staff do not have any information about the private consulting practices of doctors.

Mandatory field(s) marked with *